You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
錦欣生殖(01951.HK)擬2.89億元購買深圳中山醫院15%股權
格隆匯 01-27 22:59

格隆匯1月27日丨錦欣生殖(01951.HK)發佈公吿,於2022年1月27日,買方成都錦潤福德醫療管理有限公司(為集團因現有合約安排而持有的附屬公司)與賣方梅驊先生訂立股權轉讓協議,據此,買方同意根據其條款及條件購買而賣方同意出售深圳中山醫院15%股權,代價為人民幣2.89億元。

於完成後,深圳中山醫院將與外商獨資企業及買方訂立新合約安排,其條款及條件與現有合約安排的條款及條件大致相同,據此,與買方所持深圳中山醫院15%額外股權相關的經濟利益將與集團的業績合併入賬。因此,於收購事項及新合約安排完成後深圳中山醫院的財務業績仍將與集團的綜合賬目合併入賬,且根據與公司核數師的討論,公司確認其有權根據當前的會計原則如此行事。截至本公吿日期,目標集團於根據新合約安排透過深圳中山醫院經營業務時並無遭受任何監管機構的任何干預或阻礙。

於本公吿日期,深圳中山醫院為公司附屬公司。公司通過外商獨資企業、Jinxin Fertility HK及BVI控股公司間接持有深圳中山醫院70%股權並透過現有合約安排控制買方及曾勇先生分別所持深圳中山醫院的3.98%及5.46%(即合共9.44%)股權。深圳中山醫院的餘下20.56%股權由賣方、曾勇先生及錢敏輝女士分別持有15%、5.46%及0.10%。深圳中山醫院於2004年5月成立並開始營運,其後於2017年1月被集團收購。深圳中山醫院為民辦營利性輔助生殖服務專科醫院。

股權轉讓協議項下的收購將使集團對深圳中山醫院的控股權增至約94.44%,從而使集團(i)加強對深圳中山醫院管理及營運的控制及影響;(ii)增加應占深圳中山醫院產生的經濟效益;及(iii)於制定深圳中山醫院的業務戰略時為集團帶來更大靈活度。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account